Skip to main content
Explore URMC
menu

Lung Cancer: VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer (CLASSICAL-Lung)

Research Question:
What is the safety and tolerability of VX15/2503 when given in combination with avelumab and what dose level of VX15/2503 to be given with 10 mg/kg of avelumab every 2 weeks?

Basic Study Information

Purpose:
There are 2 phases in this study. If you are in the dose finding phase of the study, the dose level of VX15/2503 that you receive is depends on when you enter the study. The first group of subjects in this study will get a low dose of VX15/2503. If that dose is well tolerated by those subjects, then the next group of subjects will get a higher dose of VX15/2503. This will continue until the highest tolerable, safe dose of VX15/2503 is reached. The dose expansion phase will begin begin after the highest tolerable dose, or recommended phase 2 dosage (dose to be tested in expansion), has been identified in the dose finding phase of the trial.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03268057?term=VX15%2F2503-04&rank=1
Study Reference #: ILUN17100

Lead Researcher (Principal Investigator)

Lead Researcher: Megan Baumgart

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lung Cancer

Return to Search